ERS Genomics launches ‘Express License’ platform to democratise access to CRISPR/Cas9

Contributed by: GlobeNewswire

Tags

Biotechnology

More Like This

PR Newswire associated0

ToolGen Files Patent Infringement Lawsuit Against Vertex in the United Kingdom

PR Newswire associated0

ToolGen Files Patent Infringement Lawsuit Against Lonza in the Netherlands

Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

PR Newswire associated0

Solvias to Perform Release Testing on World's First CRISPR-based Gene-Editing Therapy

BIOMAY LAUNCHES FDA-GRADE CRISPR/CAS9 NUCLEASE FOR OFF-THE-SHELF PURCHASE

Cassidy Bio Launches with the Goal to Develop Safer, More Scalable Gene Editing Therapies

Jumpcode Genomics and Takara Bio USA Announce Global Patent Partnership

PR Newswire associated0

Chromatin Bioscience Announces Collaboration with Purespring Therapeutics